THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 7, 2008--Amgen (NASDAQ:AMGN), today announced results of voting at the company's Annual Meeting of Stockholders, held at the Four Seasons Hotel Westlake Village in Westlake Village, Calif. Approximately 86.9 percent of outstanding shares were represented at the meeting.
The director nominees David Baltimore, Frank J. Biondi, Jr., Jerry D. Choate, Vance D. Coffman, Frederick W. Gluck, Frank C. Herringer, Gilbert S. Omenn, Judith C. Pelham, J. Paul Reason, Leonard D. Schaeffer and Kevin W. Sharer were each reelected to Amgen's Board of Directors, each receiving a majority of 'For' votes of the votes cast and each was elected by no less than 87.7 percent of the votes cast. With the reelection of these directors, Amgen currently has 11 directors.
With approximately 97.6 percent of 'For' votes of the votes cast, stockholders ratified Ernst & Young as Amgen's independent registered public accountants for the year ending Dec. 31, 2008.
Stockholders approved a nonbinding resolution recommending that the company eliminate the supermajority voting requirements in its bylaws and certificate of incorporation. The proposal received approximately 78.7 percent of votes cast 'For' the proposal. Stockholders rejected a proposal relating to animal welfare. The proposal received less than 4.9 percent of the votes cast 'For' the proposal.
The final vote totals will be included in the company's next quarterly report to be filed with the Securities and Exchange Commission.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.
CONTACT: Amgen, Thousand Oaks
David Polk: 805-447-4613 (media)
Arvind Sood: 805-447-1060 (investors)
SOURCE: Amgen